Forvis Mazars Group’s Post

[#Csuite2025] Confidence in #LifeSciences and #pharmaceuticals remains strong, even as capital becomes harder to access. Denis Ribon, Managing Partner and Chairman of ARCHIMED, explains why specialist investors are focusing on the sector’s core strengths: 🔹 Resilient demand 🔹 Rapid scientific innovation 🔹 Shift toward value-based care To adapt, companies are sharpening capital discipline and building strategic partnerships to support sustainable growth. Read more: https://fvmz.rs/6044SjY6C For more insights, explore our C-suite barometer life sciences & pharmaceuticals report: https://fvmz.rs/6048SjYB8